Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Hold” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has been given an average rating of “Hold” by the nine ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $24.8571.

Several equities research analysts recently commented on the company. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th. Wedbush boosted their price target on Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Truist Financial cut their price target on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, Wall Street Zen raised shares of Xencor from a “strong sell” rating to a “hold” rating in a research report on Saturday.

Xencor Stock Up 2.4%

XNCR stock opened at $22.10 on Friday. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -10.18 and a beta of 0.85. The company’s fifty day simple moving average is $16.11 and its 200 day simple moving average is $13.50. Xencor has a 12-month low of $7.02 and a 12-month high of $22.22.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The firm had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same period last year, the business posted ($0.41) EPS. The business’s revenue was up 17.4% compared to the same quarter last year. Research analysts expect that Xencor will post -3 earnings per share for the current year.

Institutional Investors Weigh In On Xencor

Several hedge funds and other institutional investors have recently bought and sold shares of XNCR. AQR Capital Management LLC acquired a new position in shares of Xencor during the first quarter valued at about $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Xencor by 9.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after buying an additional 3,692 shares during the period. Goldman Sachs Group Inc. increased its position in Xencor by 89.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after buying an additional 344,088 shares in the last quarter. Creative Planning increased its position in Xencor by 25.3% in the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 3,661 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Xencor by 170.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company’s stock worth $2,594,000 after buying an additional 208,182 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.